Research Topics
| Martine van GlabbekeSummaryAffiliation: EORTC Data Center Country: Belgium Publications
| Collaborators
|
Detail Information
Publications
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomasM van Glabbeke
EORTC Data Center, Av Mounier 83 11, B1200, Brussels, Belgium
Eur J Cancer 38:543-9. 2002....- Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials GrouMartine van Glabbeke
European Organisation for Research and Treatment of Cancer Data Center, Av E Mounier, 83, Bte 8, B1200 Brussels, Belgium
J Clin Oncol 23:5795-804. 2005..This study is based on the European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group randomized trial comparing two doses of imatinib in advanced disease... - Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone M van Glabbeke
European Organization for Research and Treatment of Cancer Data Center, Brussels, Belgium
J Clin Oncol 17:150-7. 1999.... - Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort studyElizabeth C Moser
EORTC Data Centre, Brussels, Belgium
Haematologica 91:1481-8. 2006..Second cancer has been associated with non-Hodgkin's Lymphoma (NHL) treatment, but few studies have addressed this issue considering specific treatments... - Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials GrMartine van Glabbeke
EORTC Data Center, Av E Mounier, 83, Bte 8, B1200, Brussels, Belgium
Eur J Cancer 42:2277-85. 2006..A multivariate risk calculator that can be used in the clinic for individual patients is proposed... - Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphomaElizabeth C Moser
European Organisation for Research and Treatment of Cancer EORTC Data Center, Brussels, Belgium
Int J Radiat Oncol Biol Phys 66:1168-77. 2006..We evaluated the impact of radiotherapy on outcome in PR patients treated in four successive European Organization for Research and Treatment of Cancer trials for aggressive NHL... - Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005Jaap Verweij
Erasmus University Medical Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
Eur J Cancer 43:974-8. 2007..In 2 patients (0.2%) a possible cardiotoxic effect of imatinib could not fully be excluded. The current analysis of a large randomised prospective study could not confirm previous suggestions of imatinib induced cardiac toxicity... - Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma GroupMichael Leahy
Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 4BX, UK, and Erasmus University Medical Center, Rotterdam, Netherlands
Eur J Cancer 43:308-15. 2007..In the non-GIST group, this PFS is in the range of other agents considered active in STS, and may predict for more substantial first line activity. Further investigation in STS other than GIST appears warranted... - Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer GroupJulie Francart
European Organisation for Research and Treatment of Cancer
J Clin Oncol 24:3007-12. 2006..To design future phase II trials, reference values for PFSRs that correspond to drugs with insufficient (P0) and sufficient (P1) clinical activity (CA) are necessary. This article provides these values in mesothelioma... - KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumoursMaria Debiec-Rychter
Department of Human Genetics, University of Leuven and University Hospital Gasthuisberg, O and N Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium
Eur J Cancer 42:1093-103. 2006..Our findings suggest the need for differential treatment of patients with GISTs, with KIT exon 9 mutant patients benefiting the most from the 800 mg daily dose of the drug... - Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mgJohn R Zalcberg
Department of Medical Oncology, Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett Street, Melbourne, VIC 8006, Australia
Eur J Cancer 41:1751-7. 2005..1% of patients were still alive and progression free one year after cross-over. We conclude that a cross-over to high-dose imatinib is feasible and safe in GIST patients who progress on low-dose therapy... - Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma GroupIan Judson
Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK
Cancer Chemother Pharmacol 55:379-86. 2005..6%, which contains zero. It is not yet clear whether this is a significant factor in the amelioration of imatinib toxicity that occurs with time or is related to disease control, and further work is required to confirm this observation... - Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialJaap Verweij
Department of Medical Oncology, Erasmus University Medical Centre, Groene Hilledijk 301, 3075 EA Rotterdam, Netherlands
Lancet 364:1127-34. 2004..Imatinib is approved worldwide for use in gastrointestinal stromal tumours (GIST). We aimed to assess dose dependency of response and progression-free survival with imatinib for metastatic GIST... - Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma GroupAllan T Van Oosterom
Department of Oncology, Catholic University Hospital, Leuven, Belgium
Eur J Cancer 38:S83-7. 2002..In summary, imatinib is generally well tolerated and has significant activity during long-term treatment of patients with advanced GISTs... - Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-upP G Casali
Department of Cancer Medicine, Istituto Nazionale dei Tumori, Milan, Italy
Ann Oncol 19:ii35-8. 2008 
A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimensIsabelle Ray-Coquard
Centre Léon Bérard and UJOMM H E Herriot, Lyon, France
Oncologist 13:467-73. 2008..Based on a report showing a specific overexpression of HER-1 in SyS, we investigated an HER-1 inhibitor, gefitinib, in refractory SyS...- Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma IntergroupIan J Lewis
Paediatric Oncology and Haematology, St James University Hospital, Leeds, UK
J Natl Cancer Inst 99:112-28. 2007..It was then proposed that survival could be improved by increasing the planned dose intensity of cisplatin and doxorubicin... - Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancerJacques Bernier
Department of Radio Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
N Engl J Med 350:1945-52. 2004..We compared concomitant cisplatin and irradiation with radiotherapy alone as adjuvant treatment for stage III or IV head and neck cancer... - Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinomaSophie D Fossa
Department of Oncology, The Norwegian Radium Hospital, Oslo, Norway
Cancer 101:533-40. 2004..In 1995, preclinical and clinical data indicated an improvement of these results if IFN was combined with 13-cis retinoic acid (CRA)... - Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-upP G Casali
Department of Cancer Medicine, Istituto Nazionale dei Tumori, Milan, Italy
Ann Oncol 19:ii89-93. 2008